The Trendlines Group (SGX:42T) entered into an asset purchase agreement with Trendlines Labs to transfer its Trendlines Innovation Labs business division, according to a filing with the Singapore Exchange on Wednesday.
The purchase consideration comprises royalties from specific customer projects with a sharing structure from 25% to 75% and a revenue share of 5% of annual net revenues, which will be paid for 10 years starting from January capped at SG$2.4 million.
Under the agreement, Trendlines Labs will also have the option to acquire Trendlines Medical Shanghai Innovation Centre, Trendlines Labs Management and the business division of Trendlines Labs Singapore.
Shares of the healthcare services provider surged over 17% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。